Emergent Product Development
Gaithersburg Inc.
Dba Emergent Product Development
Gaithersburg Inc
CAGE Code: 057Y1
NCAGE Code: 057Y1
Status: Active
Type: Manufacturer
Dun & Bradstreet (DUNS): 189488554
Summary
Emergent Product Development, Gaithersburg Inc., Dba Emergent Product Development, Gaithersburg Inc is an Active Manufacturer with the Cage Code 057Y1 and is tracked by Dun & Bradstreet under DUNS Number 189488554..
Address
300 Professional Dr
Gaithersburg MD 20879-3428
United States
Points of Contact
No Points of Contact...
Related Information
People who viewed this 'CAGE Code' also viewed...
Hypertek Inc Global Satcom Technology Inc Zigler Ari Mainstreet 407 Glazing Llc Jadco Engineering Inc Trevigen, Inc. Row, Klon O Inc Electra Executive Enterprise Inc Roberts Oxygen Co Blackwell Physicians, Llc Peak Technology Cellpoint Scientific, Inc. Dataport Inc Bpt Manufacturing Corporation Skytek Corp Custom Electronics Co Inc Oncor Inc Rockville Office Machines Inc. Orient Express Delivery Service Inc Biomedical Research And Development
Frequently Asked Questions (FAQ) for CAGE 057Y1
- What is CAGE Code 057Y1?
- 057Y1 is the unique identifier used by NATO Organizations to reference the physical entity known as Emergent Product Development Gaithersburg Inc. Dba Emergent Product Development Gaithersburg Inc located at 300 Professional Dr, Gaithersburg MD 20879-3428, United States.
- Who is CAGE Code 057Y1?
- 057Y1 refers to Emergent Product Development Gaithersburg Inc. Dba Emergent Product Development Gaithersburg Inc located at 300 Professional Dr, Gaithersburg MD 20879-3428, United States.
- Where is CAGE Code 057Y1 Located?
- CAGE Code 057Y1 is located in Gaithersburg, MD, USA.
Contracting History for CAGE 057Y1 Most Recent 25 Records
- 75A50123C00037
- Medical Countermeasures (Mcm) That Can Be Deployed In The Event Of A Filovirus Outbreak Are A Crucial Component To The United States Government?S (Usg?S) Outbreak Response Plan. Biomedical Advanced Research And Development Authority (Barda) Is Seekin
- 31 Jul 2023
- Medical Countermeasures (Mcm) That Can Be Deployed In The Event Of A Filovirus Outbreak Are A Crucial Component To The United States Government?S (Usg?S) Outbreak Response Plan. Biomedical Advanced Research And Development Authority (Barda) Is Seekin
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $59,974,026.00
- Department Of Health And Human Services (Hhs)
- HHSD200200824959I
- Warmbase Smallpox Vaccine Manufacturing
- 28 Apr 2021
- Warmbase Smallpox Vaccine Manufacturing
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $120,007,349.93
- Department Of Health And Human Services (Hhs)
- W81XWH19C0193
- Analgesic Ketamine-Clinical Trial
- 31 Mar 2023
- Analgesic Ketamine-Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $11,060,720.09
- Department Of Defense (Dod)
- W81XWH19C0193
- Analgesic Ketamine-Clinical Trial
- 7 Sep 2023
- Analgesic Ketamine-Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $6,859,876.72
- Department Of Defense (Dod)
- W81XWH19C0193
- Analgesic Ketamine-Clinical Trial - Incremental Funding
- 18 Mar 2021
- Analgesic Ketamine-Clinical Trial - Incremental Funding
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $11,060,720.09
- Department Of Defense (Dod)
- W81XWH19C0193
- Analgesic Ketamine-Clinical Trial
- 27 Oct 2022
- Analgesic Ketamine-Clinical Trial
- Army Med Res Acq Activity
- Department Of Defense (Dod)
- $17,848,531.73
- Department Of Defense (Dod)
- W81XWH19C0193
- Analgesic Ketamine-Clinical Trial
- 2 Dec 2022
- Analgesic Ketamine-Clinical Trial
- W4pz Usa Med Rsch Acquis Act
- Department Of Defense (Dod)
- $17,848,531.73
- Department Of Defense (Dod)
- 75A50119C00071
- Eo14042 Vax Eo
- 25 Oct 2021
- Eo14042 Vax Eo
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $529,216,465.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00071
- Administrative Action
- 19 May 2023
- Administrative Action
- Aspr/Orm-Sns
- Department Of Health And Human Services (Hhs)
- $649,154,060.46
- Department Of Health And Human Services (Hhs)
- 75A50119C00071
- Modification To Exchange Cans
- 29 Sep 2021
- Modification To Exchange Cans
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $529,216,465.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00071
- Administrative Action
- 18 May 2023
- Administrative Action
- Aspr/Orm-Sns
- Department Of Health And Human Services (Hhs)
- $529,184,060.46
- Department Of Health And Human Services (Hhs)
- 75A50119C00071
- Acam2000, Smallpox (Vaccinia) Vaccine, Live (Acam)
- 5 Jul 2021
- Acam2000, Smallpox (Vaccinia) Vaccine, Live (Acam)
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $529,216,465.00
- Department Of Health And Human Services (Hhs)
- 75A50119C00071
- Administrative Action
- 6 Oct 2022
- Administrative Action
- Aspr/Orm-Sns
- Department Of Health And Human Services (Hhs)
- $529,216,465.00
- Department Of Health And Human Services (Hhs)
- HHSN272201400038C
- Development Of Vaccine Formulations Effective Against Niaid Priority Pathogens
- 15 Nov 2022
- Development Of Vaccine Formulations Effective Against Niaid Priority Pathogens
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $29,701,452.70
- Department Of Health And Human Services (Hhs)
- HHSO100201600030C
- Eo14042 Emergent Av7909 Anthrax Vaccine
- 6 Oct 2023
- Eo14042 Emergent Av7909 Anthrax Vaccine
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $1,200,742,203.00
- Department Of Health And Human Services (Hhs)
- HHSN272200800040C
- Avp-21D9 Anthrax Monoclonal Antibody
- 10 Jun 2021
- Avp-21D9 Anthrax Monoclonal Antibody
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $18,105,370.48
- Department Of Health And Human Services (Hhs)
- HHSO100201700001C
- Update Period Of Performance For Clin 0003
- 13 Sep 2023
- Update Period Of Performance For Clin 0003
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $32,952,759.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600030C
- Eo14042 Emergent Av7909 Anthrax Vaccine
- 2 Dec 2021
- Eo14042 Emergent Av7909 Anthrax Vaccine
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $1,121,242,203.00
- Department Of Health And Human Services (Hhs)
- HHSO100201700001C
- Update Key Personnel
- 12 Dec 2022
- Update Key Personnel
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $32,952,759.00
- Department Of Health And Human Services (Hhs)
- HHSO100201600030C
- Eo14042 Emergent Av7909 Anthrax Vaccine
- 21 Nov 2023
- Eo14042 Emergent Av7909 Anthrax Vaccine
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $1,275,742,139.10
- Department Of Health And Human Services (Hhs)
- HHSO100201600030C
- Eo14042 Emergent Av7909 Anthrax Vaccine
- 30 Mar 2023
- Eo14042 Emergent Av7909 Anthrax Vaccine
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $1,125,742,203.00
- Department Of Health And Human Services (Hhs)
- HHSO100201700001C
- Add Hhsar Clause 352.232-71 And Ipp Language
- 22 Sep 2022
- Add Hhsar Clause 352.232-71 And Ipp Language
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $32,952,759.00
- Department Of Health And Human Services (Hhs)
- HHSN272200800051C
- Funding Action Only
- 8 Jun 2021
- Funding Action Only
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $26,710,105.63
- Department Of Health And Human Services (Hhs)
- HHSO100201700001C
- Update Period Of Performance For Clin 0003
- 25 Jan 2023
- Update Period Of Performance For Clin 0003
- Barda - Aspr / Daappo / Barda Dcma
- Department Of Health And Human Services (Hhs)
- $32,952,759.00
- Department Of Health And Human Services (Hhs)
- HHSN272201400038C
- Development Of Vaccine Formulations Effective Against Niaid Priority Pathogens
- 13 Mar 2023
- Development Of Vaccine Formulations Effective Against Niaid Priority Pathogens
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $30,177,860.81
- Department Of Health And Human Services (Hhs)